News
04-04-2012, 01:10 AM
A new class of agents known as c-Src inhibitors is being tested in a number of different ways to treat breast cancer, but researchers at Georgetown Lombardi Comprehensive Cancer Center caution that they should not be used in combination with estrogen to treat endocrine resistant breast cancer...
More... (http://www.medicalnewstoday.com/releases/243676.php)
More... (http://www.medicalnewstoday.com/releases/243676.php)